[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solid-organ-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solid-organ-transplant":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,71,102,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100637182","pediatric-solid-organ-transplant-patient-engagement-using-an-educational-tablet-based-gamemystic-wizard-100637182",false,"NCT07609303","Pediatric Solid Organ Transplant Patient Engagement Using an Educational Tablet-Based Game(Mystic Wizard)","Pediatric Solid Organ Transplant Patient Engagement Using an Educational Tablet-Based Game: A Prospective, Mixed Methods Study","Inclusion Criteria:\n\n* Pediatric solid organ transplant recipient (e.g., liver, kidney, heart)\n* Age 7-14 years\n* Currently admitted to Lucile Packard Children's Hospital\n* Able to understand and interact with a tablet-based game in English\n* Parent or legal guardian available to provide consent\n\nExclusion Criteria:\n\n* Significant cognitive impairment or developmental condition limiting ability to participate in gameplay or surveys\n* Acute medical instability\n* Severe visual, hearing, or motor impairment preventing interaction with the game\n* Non-English speaking participant","ALL","7 Years","14 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","Children and teenagers who receive a solid organ transplant (such as a kidney, liver, or heart) must take medications every day to keep their new organ healthy. Taking these medications correctly and on time is one of the most important parts of staying well after a transplant, but it can be hard for young patients to understand why this matters and to keep up with their routines. Doctors and nurses usually teach patients about their transplant through conversations, which may not always be engaging or easy for kids to remember.\n\nThis study looks at a new way to help young transplant patients learn about their condition and their medications: an educational game played on a tablet. The purpose of the study is to find out what patients think of the game and how well it works for them. Researchers want to know whether young patients find the game acceptable and enjoyable, whether it is easy to use, whether it makes them feel motivated and capable, and how engaged they feel while playing.\n\nTo do this, patients will play the tablet game and then share their experiences. After playing, they will take part in a small group interview where they talk about what they liked, what was confusing, and whether the game helped them understand their transplant and medications. They will also fill out short questionnaires about how easy the game was to use and how engaging it felt.\n\nThe researchers' hypothesis is that pediatric solid organ transplant patients will find the educational tablet-based game acceptable, easy to use, and engaging, and that it will be a welcome and helpful tool for learning about their transplant care. The findings will help guide whether this kind of game could be used to support transplant education for children and teens.",[27],"Solid Organ Transplant",[29],"Education","NOT_YET_RECRUITING","2026-06-02",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":21},"2026-07-01",{"date":38,"type":21},"2027-06-30",{"name":40,"class":41},"Stanford University","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100640821","phase-1-rituximab-for-ptld-prevention-in-solid-organ-transplant-recipients-with-ebv-dnaemia-100640821","NCT07614282","Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia","A Phase 1 Trial of Rituximab in Addition to Standard of Care for the Prevention of Post-Transplant Lymphoproliferative Disorder in Solid Organ Transplant Recipients With EBV DNAemia","Inclusion Criteria:\n\n1. Patients must have received a solid organ transplant.\n2. Patients must not have a diagnosis of PTLD (confirmed with CT or PET imaging, and if there are concerning lesions present on imaging - a biopsy must be performed to rule out PTLD), or history of PTLD\n3. Age ≥ 18\n4. Patients must have EBV DNAemia ≥ 1000 IU\u002FmL (plasma) on two consecutive measurements at least 1 week apart and within a 6-week period. The second measurement must be within 4 weeks of enrollment.\n5. Patients must have had reduction in their immunosuppression according to institutional best practices prior to enrollment OR have documented clinical rationale for which immunosuppression may not be safely reduced (e.g. due to organ transplant rejection)\n6. Patients with a positive hepatitis B virus (HBV) core antibody and negative HBV surface antigen consistent with prior HBV exposure must be to take appropriate anti-viral prophylaxis. Patients with evidence of chronic HBV infection must have undetectable HBV viral load on the most recent test results obtained within the last year and received suppressive therapy.\n7. Participants with a history of hepatitis C virus (HCV) infection must have an undetectable viral load. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 28 days prior to consent.\n8. Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test (must be within 28 days prior to registration). Participants with known HIV must have a CD4 count checked within 28 days prior to registration, but may proceed with therapy regardless of CD4 count.\n9. Ability to understand and the willingness to sign a written informed consent document. If an individual lacks capacity, a legally acceptable surrogate\u002Flegally authorized representative should be able to understand and willing to sign a written informed consent document.\n10. Must have a life expectancy \\> 6 months\n11. Must not have an active malignancy unless in remission and with life expectancy \\> 2 years with exception of patients diagnosed with basal cell or squamous cell carcinoma of the skin or carcinoma \"in situ\" of the cervix or breast who are eligible even if diagnosed within 2 years. If patients have another malignancy that was treated within the last 2 years, such patients may be enrolled, if the likelihood of requiring systemic therapy for this other malignancy within 2 years is less than 10%, as determined by an expert in that particular malignancy at CUIMC, and after consultation with the Principal Investigator. Hormone therapy for treated prostate and breast cancer is allowed.\n\nExclusion criteria:\n\n\\- Under the age of 18 years","18 Years",{"count":51,"type":21},28,[53],"PHASE1","People who have received a solid organ transplant can develop ongoing Epstein-Barr virus (EBV) infection in the blood, which increases the risk of a serious cancer called post-transplant lymphoproliferative disorder (PTLD). This study will test whether rituximab, a drug approved by the U.S. Food and Drug Administration (FDA) for several immune-related conditions, can safely clear EBV from the blood and help prevent PTLD when lowering immune-suppressing medications is not possible or effective. The study includes an initial smaller group focused on determining whether EBV can be cleared, followed by a larger group designed to determine whether treatment lowers the risk of developing PTLD. Researchers will also monitor side effects, transplant organ health, and immune system changes to better understand treatment safety and benefit.",[56,57,27],"PTLD","Epstein Barr Virus (EBV) Infection",[59,27,60,61],"PTLD Prevention","Rituximab","Epstein Barr Virus (EBV)","2026-05-22",{"date":64,"type":34},"2026-05-29",{"date":66,"type":21},"2026-07",{"date":68,"type":21},"2028-07",{"name":70,"class":41},"Jennifer Amengual",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":49,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100556778","phase-4-utilising-genotype-informed-bayesian-dosing-of-tacrolimus-in-children-post-solid-organ-transplantation-100556778","NCT06529536","Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.","Genotype Informed Bayesian Dosing of Tacrolimus in Solid Organ Transplant- Pharmacogenomic Implementation in Children","BRUNO-PIC","Participants will be assigned to the prospective arm if treated at Royal Children's Hospital who are receiving a solid organ transplant (SOT) (excluding repeat graft in liver transplant recipients, or lung or intestinal transplant) and who will be on tacrolimus as one of the main immunosuppressants post-transplant.\n\nInclusion Criteria:\n\n* Age 1-18 years of age\n* Kidney, liver or heart transplant recipients\n* Participant and\u002For parent consent to the study (prospective arm only)\n\nExclusion Criteria:\n\n* Previous liver transplant.\n* Lung OR Intestinal transplant.\n* Insufficient time before transplant for pharmacogenomic analysis (prospective arm only)\n* Immunosuppressant regimen not containing tacrolimus immediate release product\n* Known hypersensitivity to tacrolimus and\u002For its formulation.","1 Year",{"count":81,"type":21},45,[83],"PHASE4","This study aims to evaluate the efficacy of genotype-informed Bayesian dosing of tacrolimus in optimising drug exposure among paediatric solid organ transplant recipients. By tailoring tacrolimus dosage based on individual genetic makeup and using Bayesian modeling to predict drug levels, the researchers hope to increase the likelihood of achieving therapeutic drug concentrations while minimising the risk of adverse events associated with subtherapeutic or supratherapeutic exposure.",[27],[87,88,89,90],"Tacrolimus","Pharmacogenomics","Bayesian","Paediatrics","RECRUITING","2026-02-22",{"date":94,"type":34},"2026-02-25",{"date":96,"type":34},"2024-08-05",{"date":98,"type":21},"2027-08-02",{"name":100,"class":41},"Murdoch Childrens Research Institute",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":49,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100481537","multi-center-molecular-diagnosis-and-host-response-of-respiratory-viral-infections-in-pediatric-transplant-recipients-100481537","NCT05550298","Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients","Recipient Inclusion Criteria\n\n* Less than 18 years at the time of anticipated transplant\n* Participant meets one of the following criteria:\n\n  1. scheduled to receive allogeneic hematopoietic cell transplant within 14 days of enrollment or\n  2. Scheduled to or received solid organ transplant within 7 days before or after enrollment\n* Participant is receiving care at the time of enrollment at one of the study participating institutions.\n* Parent\u002Fguardian willing and able to provide informed consent, and if appropriate, child willing and able to provide informed assent.\n\nDonor Inclusion Criteria\n\n* Donor for HCT recipient enrolled on the VIPER study.\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\nRecipient Exclusion Criteria\n\nNone\n\nDonor Exclusion Criteria\n\n* Is not an HCT donor for a participant enrolled on the VIPER study.\n* Not available to provide pre-transplant research blood sample.",{"count":109,"type":21},2000,"OBSERVATIONAL","The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT).\n\nPrimary Objective\n\nTo determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors.\n\nSecondary Objectives:\n\n* To develop and validate a classifier based on pre-transplant immunological profile predictive of developing an acute respiratory viral infection (aRVI), with RSV\u002FPIV3\u002FHMPV\u002FSARS-CoV-2 through one-year post-transplant among survivors.\n* To develop and validate a classifier based on Day +100 post-transplant immunological profiles predictive of developing an acute respiratory viral infection (aRVI),with RSV\u002FPIV3\u002FHMPV\u002FSARS-CoV-2 through one-year post-transplant among survivors .",[113,27,114],"Hematopoietic Cell Transplant","Respiratory Viral Infection","2025-09-29",{"date":117,"type":34},"2025-10-02",{"date":119,"type":34},"2022-12-13",{"date":121,"type":21},"2029-08",{"name":123,"class":41},"Arkansas Children's Hospital Research Institute",27,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":132,"sex":16,"minAge":49,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":101},"100513694","iparent2parent-program-for-parents-of-pediatric-solid-organ-transplant-recipients-100513694","NCT05968807","iParent2Parent Program for Parents of Pediatric Solid Organ Transplant Recipients","\"The Isolation I Feel is Profound\": The iParent2Parent Online Peer Support Program for Parents of Pediatric Solid Organ Transplantation Recipients","Mentee Inclusion Criteria:\n\n* Parent of a patient under 18 years of age who received a solid organ transplant and is at least two months post-transplant,\n* Access to a device (e.g., smart phone, tablet, computer) capable of using free WhatsApp software, and\n* English-speaking.\n\nMentor Inclusion Criteria:\n\n* Parent of a patient under 21 years of age who received a solid organ transplant and is at least one year post-transplant,\n* Nominated by their child's healthcare team as a good candidate to act in the mentor role (e.g., good communication skills, positive adaptation and adjustment post-transplant, strong support network),\n* Access to a device (e.g., smart phone, tablet, computer) capable of using free WhatsApp software, and\n* English-speaking.\n\nExclusion Criteria:\n\n* Non-English speaking.",true,"75 Years",{"count":135,"type":21},55,[24],"The iParent2Parent (iP2P) program is a new, innovative virtual mentorship program that will connect parents one-to-one with other parents of pediatric solid organ transplant (SOT) recipients who are trained to offer vital peer support and mentorship. Parents of children who received a SOT at The Hospital for Sick Children will be invited to participate as mentors and mentees (randomized into the iP2P or control group). The iP2P program can decrease feelings of isolation, improve mental health and have a long-term positive impact on patient health. This research will increase our understanding of one-to-one peer support and leverage eHealth technologies to improve the access to and acceptability of parent peer support interventions.",[27],[140,141,142,143],"Peer Support Mentorship","Parent Support Mentorship","Pediatrics","Transplant","2025-05-13",{"date":146,"type":34},"2025-05-16",{"date":148,"type":34},"2023-08-01",{"date":150,"type":21},"2026-06-26",{"name":152,"class":41},"The Hospital for Sick Children"]